Lobular Carcinoma In Situ (LCIS)
- Neoplastic proliferation within ducts/lobules (fill and expand lobules)
- Associated with loss of expression of E-Cadherin
- Incidental finding (not associated with calcifications or stromal reactions found by mammography)
- LCIS is bilateral 20-40% of cases
- Morphology
- Mucin-positive signet ring cells often present
- E-Cadherin negative cells
- Uniform cells with oval/round nuclei
- Pagetoid spread (cells present between the myoepithelial layer and over lying luminal epithelium
- Typically ER/PR positive
- Her-2 is not overexpressed
- 1%/year risk of developing an invasive tumor (similar to low-grade DCIS) – Lifetime risk is ~25-35% (20-30 year time period)
- Cancer risk is equal in contralateral breast (unlike DCIS)
- Pleomorphic variant of LCIS
- High grade nuclei
- May be ER negative
- Some may overexpress Her-2
- May be separate entity from typical LCIS
Photomicrographs
![Breast - Lobular Carcinoma In Situ (LCIS)](https://www.pathmd.com/wordpress/wp-content/uploads/2017/09/Breast_LCIS_HE-1-1024x768.jpeg)
LCIS characterized by filling and expansion of the lobular unit.
![Breast - Lobular Carcinoma In Situ (LCIS)](https://www.pathmd.com/wordpress/wp-content/uploads/2017/09/Breast_LCIS_HE-2-1024x768.jpeg)
![Breast - Lobular Carcinoma In Situ (LCIS)](https://www.pathmd.com/wordpress/wp-content/uploads/2017/09/Breast_LCIS_HE-3-1024x768.jpeg)
References
Kumar, Vinay, Abul K. Abbas, and Jon C. Aster. Robbins and Cotran Pathologic Basis of Disease. Ninth edition. Philadelphia, PA: Elsevier/Saunders, 2015. p. 1045.